Benefits
Knee osteoarthritis — pain, stiffness, function
In knee OA patients over 120 days, Boswellin produced significant improvements in VAS pain, WOMAC stiffness, and physical function vs placebo. Radiographic assessment showed improved knee joint gap and reduced osteophytes — unusual structural improvement vs symptom-only benefits typical of OA supplements. Also reduced hs-CRP, an inflammation biomarker.
Dose-finding OA benefits
A multi-center RCT in newly-diagnosed OA patients compared placebo, 150 mg, and 300 mg Boswellin Super twice daily. Both Boswellin doses significantly improved VAS pain, WOMAC scores, Lequesne Functional Index, EQ-5D quality of life, and 6-minute walk test vs placebo. Effects were visible as early as 5 days — unusually fast onset for a botanical anti-inflammatory.
Multi-bioactive standardization advantage
Standardizing to 30% AKBA plus 50-55% total β-boswellic acids (rather than AKBA alone) provides synergistic coverage of 5-LO inhibition (AKBA) plus broader anti-inflammatory pathways (BBA, KBBA, ABBA). Some research suggests the full β-boswellic acid spectrum may outperform isolated high-AKBA preparations.
Exercise-induced muscle soreness
In recreationally-active men, 60 mg/day standardized Boswellia (30% AKBA) reduced delayed-onset muscle soreness and inflammation markers vs placebo. Useful for athletes and active populations beyond the traditional OA application.
5-LO pathway inhibition (distinct mechanism)
Most anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) pathways. Boswellia uniquely targets 5-lipoxygenase (5-LO), which produces leukotrienes — a separate inflammatory pathway. This complementary mechanism means boswellia can be combined with NSAIDs for additive effects without competing at the same target.
Excellent long-term safety
A long-term safety assessment showed no significant changes in vital signs, hematology, or biochemistry vs placebo. No serious adverse events in any boswellia OA trial. Unlike chronic NSAID use (GI bleeding, cardiovascular risk), long-term boswellia has an unusually clean safety profile for an anti-inflammatory.
Mechanism of action
5-lipoxygenase (5-LO) inhibition
AKBA is a potent inhibitor of 5-LO, blocking the conversion of arachidonic acid to leukotrienes (LTB4, LTC4, LTD4, LTE4). Leukotrienes drive inflammatory cell recruitment, bronchoconstriction, and joint inflammation. This mechanism is distinct from COX inhibition (NSAIDs).
NF-κB pathway modulation
Boswellic acids inhibit NF-κB activation, the master transcription factor for inflammatory gene expression. NF-κB drives production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) — boswellia's downstream cytokine effects trace back to this transcriptional mechanism.
Matrix metalloproteinase (MMP) inhibition
Boswellic acids inhibit MMPs — enzymes that degrade cartilage extracellular matrix in OA progression. This explains how boswellia can produce radiographic joint improvement rather than just symptomatic relief — by actually slowing cartilage breakdown.
Caspase inhibition
Boswellic acids inhibit caspase-mediated protein degradation and apoptosis pathways relevant to chondrocyte (cartilage cell) death in OA. Preserving chondrocyte viability supports cartilage maintenance over time.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 48 patients with knee OA. Intervention: 169.33 mg Boswellin BID for 120 days (the longest boswellia OA trial at the time).
48 patients with knee OA
Randomized, double-blind, placebo-controlled trial in 48 patients with knee OA. Intervention: 169.33 mg Boswellin BID for 120 days (the longest boswellia OA trial at the time). Significant improvements in VAS pain, WOMAC stiffness, and physical function vs placebo. Radiographic improvements in knee joint gap and reduced osteophytes. Reduced serum hs-CRP. No serious adverse events. Published in Phytotherapy Research.
Multi-center randomized double-blind placebo-controlled trial in 105 newly-diagnosed OA patients. Three arms: placebo, Boswellin Super 150 mg BID, or 300 mg BID for 90 days.
Clinical population described in trial publication.
Multi-center randomized double-blind placebo-controlled trial in 105 newly-diagnosed OA patients. Three arms: placebo, Boswellin Super 150 mg BID, or 300 mg BID for 90 days. Both Boswellin doses significantly improved VAS, WOMAC, Lequesne Functional Index, EuroQol-5D quality of life, and 6MWT vs placebo. Effects visible at day 5. Published in Frontiers in.